MARKET

LGND

LGND

Ligand Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

73.23
+1.28
+1.78%
After Hours: 73.23 0 0.00% 17:46 04/03 EDT
OPEN
71.84
PREV CLOSE
71.95
HIGH
74.59
LOW
70.96
VOLUME
565.26K
TURNOVER
--
52 WEEK HIGH
130.50
52 WEEK LOW
57.24
MARKET CAP
1.21B
P/E (TTM)
2.494
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LGND stock price target is 186.00 with a high estimate of 237.00 and a low estimate of 134.00.

EPS

LGND News

More
  • Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
  • Business Wire · 1d ago
  • XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
  • Seeking Alpha - Article · 4d ago
  • Blair likes Incyte in premarket analyst action
  • Seeking Alpha - Article · 03/24 11:53
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About LGND

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
More

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.